The adverse events associated with this triple-targeted regimen included one case of alanine aminotransferase increase (grade 3), aspartate aminotransferase increase (grade 3), rash (grade 2), and peripheral edema (grade 1); one case of dyspnoea (grade 1); and one case of pyrexia (grade 2) (Table 4). The gene discussed is GPT; the disease is Fever.